arginyl-glycyl-aspartic acid has been researched along with Hypercalcemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, JT; Devadas, B; Duffin, TD; Engleman, VW; Finn, MB; Freeman, SK; Green, NF; Griggs, DW; Keene, JL; Kleine, HP; Landis, BH; Lantz, MK; Lu, HF; Malecha, JW; Marrufo, LD; Meyer, DM; Miller, LM; Nagarajan, SR; Nickols, GA; Nickols, MA; Pegg, JA; Rico, JG; Rogers, TE; Ruminski, PG; Russell, MA; Shannon, KE; Steininger, C; Westlin, MM; Williams, ML; Zhu, J | 1 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Hypercalcemia
| Article | Year |
|---|---|
R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.
Topics: Amino Acids; Animals; Antineoplastic Agents; Colonic Neoplasms; Hypercalcemia; Integrin alphaVbeta3; Isomerism; Melanoma; Mice; Mice, Inbred Strains; Molecular Mimicry; Oligopeptides; Skin Neoplasms; Xenograft Model Antitumor Assays | 2007 |